By Fineline Cube Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced NMPA clearance to initiate a clinical study for CS08399, an MTA-cooperative PRMT5 inhibitor, in adult solid tumors and lymphomas with methylthioadenosine phosphorylase (MTAP) deficiency. The investigational drug selectively targets the PRMT5-MTA complex, significantly enhancing PRMT5 inhibition and reducing symmetric dimethylation of arginine (SDMA) levels to induce cell cycle arrest and apoptosis in MTAP-deficient tumor cells while sparing normal cells, offering a compelling safety advantage and synthetic lethality approach to cancer therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Clinical trial authorization (IND) |
| Product | CS08399 |
| Drug Class | MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor |
| Mechanism | Selective PRMT5-MTA complex targeting; synthetic lethality in MTAP deficiency |
| Indication | Adult solid tumors and lymphomas with MTAP deficiency |
| Developer | Shenzhen Chipscreen Biosciences (SHA: 688321) |
| Approval Date | 16 Mar 2026 |
Drug Profile & Mechanism
| Attribute | CS08399 Specification |
|---|---|
| Target | PRMT5 (protein arginine methyltransferase 5) – MTA-cooperative binding |
| Synthetic Lethality | MTAP deficiency creates dependency on PRMT5-MTA pathway |
| Molecular Action | • Selective inhibition of PRMT5-MTA complex • Reduces SDMA (symmetric dimethylation of arginine) levels • Induces cell cycle arrest and apoptosis |
| Selectivity | High – minimal impact on MTAP-normal cells; significant safety advantage |
| Tumor Types | Solid tumors and lymphomas with MTAP deficiency (~15% of all cancers) |
| Biomarker | MTAP loss (homozygous deletion) |
Scientific Rationale:
- MTAP Deletion: Common in cancers (glioblastoma, pancreatic, lung, bladder, lymphoma); ~15% of all tumors; results in accumulation of MTA (methylthioadenosine)
- PRMT5 Addiction: MTA binds and partially inhibits PRMT5; MTAP-deficient cells become hypersensitive to further PRMT5 inhibition
- Synthetic Lethality: CS08399 exploits this dependency, killing tumor cells while sparing normal tissue
Strategic Context & Market Opportunity
| Factor | Implication |
|---|---|
| MTAP-Deficient Cancers | 15% of all cancers (~2.5 million annual cases globally); high unmet need in aggressive tumors |
| PRMT5 Competition | Multiple PRMT5 inhibitors in development (GSK3326595, JNJ-64619178, MRTX1719); CS08399 MTA-cooperative mechanism differentiates |
| Synthetic Lethality Trend | PARP inhibitors validated approach; MTAP/PRMT5 next frontier for targeted therapy |
| Chipscreen Innovation | Extends company’s epigenetic drug discovery expertise (chidamide,西奥罗尼); China-first development strategy |
| Biomarker-Driven Strategy | MTAP IHC or CDKN2A/MTAP deletion testing enables patient selection; companion diagnostic development |
Competitive Landscape
| Competitor | Product | Mechanism | Status | CS08399 Differentiation |
|---|---|---|---|---|
| GSK | GSK3326595 | PRMT5 inhibitor (MTA-non-cooperative) | Phase I/II | MTA-cooperative binding enhances selectivity for MTAP-deficient cells |
| Johnson & Johnson | JNJ-64619178 | PRMT5 inhibitor | Phase I | Similar mechanism; CS08399 China-first development |
| Mirati | MRTX1719 | PRMT5 inhibitor (MTA-cooperative) | Phase I/II | Direct competitor; CS08399 potentially improved selectivity profile |
| Chipscreen | CS08399 | MTA-cooperative PRMT5 inhibitor | Phase I-ready | Synthetic lethality approach; minimal normal cell impact; China innovation |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase I | 2026-2028 | Safety, tolerability, MTD; MTAP-deficient tumor enrichment; SDMA biomarker validation |
| Phase II | 2028-2030 | Efficacy signals in MTAP-deleted glioblastoma, pancreatic cancer, lymphoma; combination with chemotherapy or immunotherapy |
| Regulatory Strategy | 2030-2031 | China NDA; U.S./EU IND filing; breakthrough therapy designation potential for aggressive tumors |
| Companion Diagnostic | 2026-2028 | MTAP IHC assay development and validation; CDKN2A/MTAP co-deletion NGS panel |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, synthetic lethality mechanism validation, and competitive positioning for CS08399. Actual results may differ due to PRMT5 biology complexity, MTAP testing adoption, and competitive dynamics with other epigenetic targeted therapies.-Fineline Info & Tech